A Study of an Investigational Drug for Focal Segmental Glomerulosclerosis (FSGS)

Office of Patient Recruitment

Dr. Gahl and his team at the National Human Genome Research Institute are seeking volunteers aged 18 and older with primary FSGS to participate in a research study on the effects of an experimental drug, ManNAc, on this disease. The study aims to assess the long-term safety and tolerability of ManNAc and determine whether it can reduce protein in the urine of people with FSGS.

The study includes a physical examination, a review of medical and family history, urine tests, and blood draws. Participants will need to make two inpatient visits to the NIH (each lasting 2-3 overnights) and three to four outpatient NIH visits (lasting a few hours each). ManNAc, an experimental sugar-based drug, is taken orally as a powder dissolved in water twice daily.

Travel and lodging will be covered. Compensation up to $2,000 over the course of the study will be provided.